shorturl.at/GaSpk Thrilled paper on routine WGS for children with cancer out today in @NatureMedicine , alongside wider stories bbc.co.uk/news/articles/crgk…… WGS can provide varied benefits beyond extensive molecular testing ❓Should WGS be SOC for all children with cancer?

Please help this very worthwhile charity @ItsNeverYou22 to get this law back on the table. Support the Parents of Sick Children - Support Hugh's Law chng.it/psDQjFLg via @UKChange

Thank you to all the patients and families involved in this pivotal study which proves the real time, real world evidence for the benefit of whole genome sequence in childhood cancer.

Heard of whole genome sequencing? Thanks to a national initiative, it's available to all children diagnosed with cancer in England. Our latest study shows that it can guide on treatment plans for children and reduce the number of tests they need. gosh.nhs.uk/news/world-first…

'Genome sequencing gives information about the genome that may be shared with other family members.' @AngusHodder discusses the child cancer breakthrough research that can help doctors know 'if they need to monitor children and families' #SJUK trib.al/1DqoA75 📺Sky 501

New research via @NHSgms showing WGS can improve the care of children with cancer. A great example of using innovative technology to inform individualised care, and of what we can achieve together for patients with WGS as a part of public healthcare nature.com/articles/s41591-0…

A powerful example in @NatureMedicine of how whole genome sequencing can improve clinical care in paediatric oncology and inform individualised medicine for children with cancer @AngusHodder @SarahLeiter @DrJackBartram @AditiVedi and teams @CRUKCamPaeds @NHSgms

CONGRESS #EHA2024 | Sujith Samarasinghe @GreatOrmondSt shares initial findings from the phase II ALLTogether1 DS trial evaluating blinatumomab as chemotherapy-replacement for children and young adults with Down Syndrome B-cell ALL (N=33). The primary endpoint was met, with 91% patients being MRD undetectable at the end of cycle 1. Grade 3/4 toxicity events were significantly lower compared to UKALL 2011 trial. No deaths, relapse, or secondary cancer were reported, however, a higher rate of seizures was observed. #ALLsm #leusm #MedicalCongress

Many thanks to @CRUKresearch and @GOSHCharity for funding this project. We are a team of clinicians, parents, scientists and data analysts working together #TeamScience. @DrJackBartram @milnetom68 Andrew Blake @OxfordOncology and many more collaborators. Can’t wait to get started

Goodbye multi-header microscope, over 25 years of service in @GreatOrmondSt Haematology lab. Countless lives saved, diagnoses made and educated thousands. You never complained once. Happy retirement. 🩸🔬

Pilot data supporting a role for maintenance chemotherapy following early B cell recovery after CART for B-ALL in transplant ineligible patients. Needs longer follow up and prospective study. Thanks to Maria Gabelli and @maca_moe_

Featuring our very own Dr Sujith Samarasinghe!

Exciting new cancer drug kinder than chemotherapy bbc.in/48WUxRC

Great publicity this am bbc.co.uk/news/health-677938… from our @JCO_ASCO paper (tinyurl.com/3xmm65yh) 🫵Blina is safe effective chemo-replacement for chemo-intolerant children ❓Now how should Blina be used for all children with B-ALL?

Great to see a kinder, less toxic treatment option available for some children with B-ALL. Blinatumomab has less side effects than standard chemotherapy and is fully portable, meaning it can be given on the go and patients spend less time in hospital. 👏 bbc.co.uk/news/health-677938…

Just out in @BloodJournal – our study exploring the origin of late relapses in T-ALL. Here's a short thread with our unexpected results! ashpublications.org/blood/ar…

Okay - updated version, now easily browsable. drive.google.com/file/d/12fS… This is a pdf of #ASH23 abstracts (no figures, but URLs). Organized by session, so you should be able to find something interesting by ctrl-F and then browse from there. Cover art by DALL-E. Caveats below

Last few days to apply!

Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL ascopubs.org/doi/10.1200/JCO…

Out now: our study of dual CAR T cells. In a heavily pre-treated cohort including 1/3 failing prior Kymriah, we achieved 1 yr EFS 60%. To date there have been no cases of cd19neg relapse, contrasting with our experience targeting cd19 alone ashpublications.org/blood/ar…